EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling

Sylvie Gazzeri iD, Nadiia Zubchuk iD, Elodie Montaudon, Fariba Nemati, Sarah Huot-Marchand, Giulia Berardi, Amelie Pucciarelli, Yassir Dib, Dylan Nerini, Christiane Oddou, Mylène Pezet iD, Laurence David-Boudet und 7 weitere

Life Science Alliance · 2024

DOI: 10.26508/lsa.202402873 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, 2024. Verfasst von Sylvie Gazzeri und 18 weiteren Autor:innen. Beteiligte Einrichtung: University Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences…. Hauptthemen laut MEDLINE: Calcineurin, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, ErbB Receptors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale, Fondation ARC pour la Recherche sur le Cancer, Ligue Nationale Contre le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite initial high response rates to first-line EGFR TKI, all non–small-cell lung cancer (NSCLC) with EGFR-activating mutation will ultimately develop resistance to treatment. Identification of resistance mechanisms is critical to adapt treatment and improve patient outcomes. Here, we show that a PPP3CB transcript that encodes full-length catalytic subunit 2B of calcineurin accumulates in EGFR-mutant NSCLC cells with acquired resistance against different EGFR TKIs and in post-progression biopsies of NSCLC patients treated with EGFR TKIs. Neutralization of PPP3CB by siRNA or inactivation of calcineurin by cyclosporin A induces apoptosis in resistant cells treated with EGFR TKIs. Mechanistically, EGFR TKIs increase the cytosolic level of calcium and trigger activation of a calcineurin/MEK/ERK pathway that prevents apoptosis. Combining EGFR, calcineurin, and MEK inhibitors overcomes resistance to EGFR TKI in both in vitro and in vivo models. Our results identify PPP3CB overexpression as a new mechanism of acquired resistance to EGFR TKIs, and provide a promising therapeutic approach for NSCLC patients that progress under TKI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalcineurinCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmErbB ReceptorsLung NeoplasmsMAP Kinase Signaling SystemProtein Kinase InhibitorsAnimalsFemaleHumansMiceApoptosisCell Line, TumorMice, NudeMutationXenograft Model Antitumor Assays

Substanzen

CalcineurinEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsPPP3CB protein, human

Autor:innen und Institutionen

  • University Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France sylvie.gazzeri@univ-grenoble-alpes.fr.
  • University Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team RNA Splicing, Cell Signaling and Response to Therapy, Institute for Advanced Biosciences, Grenoble, France.
  • Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, Paris, France.
  • Department of Pneumology and Physiology, Grenoble-Alpes University Hospital, Grenoble, France.
  • University Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Team Epigenetics, Immunity, Metabolism, Cell Signaling and Cancer, Institute for Advanced Biosciences, Grenoble, France.
  • University Grenoble Alpes, Inserm U1209, CNRS UMR 5309, Platform MicroCell, Institute for Advanced Biosciences, Grenoble, France.

ORCID-Profile: Sylvie Gazzeri, Nadiia Zubchuk, Mylène Pezet, Florence de Fraipont, Beatrice Eymin

Förderung

  • Institut National de la Santé et de la Recherche Médicale
  • Fondation ARC pour la Recherche sur le Cancer
  • Ligue Nationale Contre le Cancer
  • Association ESPOIR
  • Groupement des Entreprises Françaises dans la lutte contre le Cancer
  • Agir pour les Maladies Chroniques
  • Canceropole Auvergne Rhone Alpes
  • Institut National Du Cancer

Zitieren

APA

Gazzeri, S., Zubchuk, N., Montaudon, E., Nemati, F., Huot-Marchand, S., Berardi, G., Pucciarelli, A., Dib, Y., Nerini, D., Oddou, C., Pezet, M., David-Boudet, L., Ardin, C., de Fraipont, F., Maraver, A., Girard, N., Decaudin, D., Toffart, A. C., & Eymin, B. (2024). PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling. Life Science Alliance. https://doi.org/10.26508/lsa.202402873

Vancouver

Gazzeri S, Zubchuk N, Montaudon E, Nemati F, Huot-Marchand S, Berardi G, et al. PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling. Life Science Alliance. 2024. doi:10.26508/lsa.202402873

BibTeX
@article{Gazzeri2024,
  author = {Gazzeri, Sylvie and Zubchuk, Nadiia and Montaudon, Elodie and Nemati, Fariba and Huot-Marchand, Sarah and Berardi, Giulia and Pucciarelli, Amelie and Dib, Yassir and Nerini, Dylan and Oddou, Christiane and Pezet, Mylène and David-Boudet, Laurence and Ardin, Camille and de Fraipont, Florence and Maraver, Antonio and Girard, Nicolas and Decaudin, Didier and Toffart, Anne-Claire and Eymin, Beatrice},
  title = {PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling},
  journal = {Life Science Alliance},
  year = {2024},
  doi = {10.26508/lsa.202402873}
}
Kostenlos starten →